Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“EGFR+ NSCLC to SCLC: what to do today?
- Prioritize clinical trial
- If no trial, chemo + TKI
- Tarlatamab not the ‘blockbuster’ solution for most pts but DLL3 expression might help us.”
Other articles about Lung Cancer on OncoDaily.
